Aclaris Therapeutics Announces Top Line Phase 2 Results for its Anti-TSLP Monoclonal Antibody Bosakitug (ATI-045) in Atopic Dermatitis (AD)
The ADMIRATION Trial Did Not Achieve its Primary Endpoint of Percent Change in Eczema Area and Sev
The ADMIRATION Trial Did Not Achieve its Primary Endpoint of Percent Change in Eczema Area and Sev